Abstract
The gonadal steroid 17β-estradiol (E2) has shown powerful cytoprotective effect on cells. In addition to classical genomic mechanisms of action, E2 also exerts non-classical effects on intracellular signal transduction. Extensive studies during the past two decades have provided evidence that the E2-induced non-classical signaling on second messenger molecules plays a critical role in the neuroprotective effect of E2. These observations provide a unique basis for developing non-classical estrogen-like signaling activators that may have potential for clinical use in neuroprotection. In spite of the extensive research over the past decade reviewed here, we are just starting to appreciate the importance and potential of these compounds. Hence, we first describe the molecular characteristics and effects of these activators. Second, we survey recent data as to possible mechanisms underlying the ameliorative actions of selective non-classical estrogen-like signaling activation. In addition, the pitfalls and future aspects of “non-classical”-line activators and its clinical relevance will also be discussed.
Keywords: Estradiol, non-classical estrogen-like signaling activators, ANGELS, estren, compound A, compound B, neuroprotection.
CNS & Neurological Disorders - Drug Targets
Title:Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications
Volume: 12 Issue: 8
Author(s): Andrea Kwakowsky, Zsombor Koszegi, Rachel Y. Cheong and Istvan M. Abraham
Affiliation:
Keywords: Estradiol, non-classical estrogen-like signaling activators, ANGELS, estren, compound A, compound B, neuroprotection.
Abstract: The gonadal steroid 17β-estradiol (E2) has shown powerful cytoprotective effect on cells. In addition to classical genomic mechanisms of action, E2 also exerts non-classical effects on intracellular signal transduction. Extensive studies during the past two decades have provided evidence that the E2-induced non-classical signaling on second messenger molecules plays a critical role in the neuroprotective effect of E2. These observations provide a unique basis for developing non-classical estrogen-like signaling activators that may have potential for clinical use in neuroprotection. In spite of the extensive research over the past decade reviewed here, we are just starting to appreciate the importance and potential of these compounds. Hence, we first describe the molecular characteristics and effects of these activators. Second, we survey recent data as to possible mechanisms underlying the ameliorative actions of selective non-classical estrogen-like signaling activation. In addition, the pitfalls and future aspects of “non-classical”-line activators and its clinical relevance will also be discussed.
Export Options
About this article
Cite this article as:
Kwakowsky Andrea, Koszegi Zsombor, Cheong Y. Rachel and Abraham M. Istvan, Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications, CNS & Neurological Disorders - Drug Targets 2013; 12 (8) . https://dx.doi.org/10.2174/187152731131200123
DOI https://dx.doi.org/10.2174/187152731131200123 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Perspectives on Chemopreventive and Therapeutic Potential of Curcumin Analogs in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Applications of Solid-State Fermentation Process in Biological Detoxification of Industrial Wastes
Current Biochemical Engineering (Discontinued) Natural Monoclonal Antibodies and Cancer
Recent Patents on Anti-Cancer Drug Discovery Synthesis and Anti-tumor Activity Evaluation of Gallic Acid-mangiferin Hybrid Molecule
Medicinal Chemistry Targeted Therapies in Combination with Radiotherapy in Oesophageal and Gastroesophageal Carcinoma
Current Medicinal Chemistry S1P Regulation of Macrophage Functions in the Context of Cancer
Anti-Cancer Agents in Medicinal Chemistry Promising Chemoprevention of Colonic Aberrant Crypt Foci by <i>Portunus segnis</i> Muscle and Shell Extracts in Azoxymethane-Induced Colorectal Cancer in Rats
Anti-Cancer Agents in Medicinal Chemistry Levofloxacin and Indolicidin for Combination Antimicrobial Therapy
Current Drug Delivery Identification and Analysis of RNA Editing Events in Ovarian Serous Cystadenoma Using RNA-seq Data
Current Gene Therapy Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Antiproliferative Activity of <i>Cissus quadrangularis</i> L. Extract Against Human Cervical Cancer Cells: In Vitro and In Silico Analysis
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Anti Cervical Cancer Activity of Novel 5H-Thiochromeno [4,3-d]pyrimidines
Letters in Organic Chemistry Editorial: [Hot Topic: Use of Microbicides to Prevent HIV Sexual Transmission (Guest Editor: Miguel E. Quinones-Mateu)]
Current HIV Research Wnt Signaling in Renal Cancer
Current Drug Targets Human Papillomavirus Selected Properties and Related Cervical Cancer Prevention Issues
Current Pharmaceutical Design Regulating miRNA by Natural Agents as a New Strategy for Cancer Treatment
Current Drug Targets Endobronchial Ultrasound-guided Transbronchial Needle Aspiration
Reviews on Recent Clinical Trials Viral and Non-Viral Methods to Genetically Modify Dendritic Cells
Current Gene Therapy Predictive Markers for Haematological Toxicity of Pemetrexed
Current Drug Targets